Acrivon Therapeutics
ACRV
ACRV
54 hedge funds and large institutions have $161M invested in Acrivon Therapeutics in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 14 reducing their positions, and 7 closing their positions.
Holders
54
Holders Change
–
Holders Change %
0%
% of All Funds
0.78%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
7
Increased
18
Reduced
14
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
1
Goldman Sachs
New York
|
$1.39M |
| 2 |
EAM
2
Exome Asset Management
New York
|
$817K |
| 3 |
3
State Street
Boston,
Massachusetts
|
$1.58M |
| 4 |
4
Millennium Management
New York
|
$278K |
| 5 |
PCM
5
Prelude Capital Management
New York
|
$264K |
